Yacov Shacham1, Amir Gal-Oz2, Nir Flint1, Gad Keren1, Yaron Arbel1. 1. Department of Cardiology, Tel Aviv Sourasky Medical Center affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 2. Department of Nephrology, Tel Aviv Sourasky Medical Center affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
BACKGROUND: Elevated serum uric acid (UA) levels are associated with adverse outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). However, the relation between UA and acute kidney injury (AKI) in this population is unclear. We evaluated the effect of elevated UA levels on the risk to develop AKI among consecutive STEMI patients treated with primary PCI. METHODS: We performed a retrospective analysis of 1,372 consecutive patients admitted with the diagnosis of STEMI between January 2008 and February 2015. Patients were stratified into quartiles according to UA levels as follows: quartile 1, <4.7 mg/dl; quartile 2, 4.8 to <5.6 mg/dl; quartile 3, 5.7 to <6.6 mg/dl, and quartile 4, >6.7 mg/dl. RESULTS: STEMI patients with elevated UA levels had a higher frequency of AKI (4 vs. 6% vs. 10 vs. 24%; p < 0.001). In a subgroup analysis of patients with reduced baseline estimated glomerular filtration rate (≤60 ml/min/1.73 m(2)), an elevated UA level was associated with a significant risk to develop AKI, with 46% of patients developing AKI in the highest UA quartile. In a multivariate logistic regression model, for every 1-mg/dl increase in the UA concentration, the adjusted risk for AKI increased by 46% (OR = 1.46, 95% CI 1.18-1.66; p < 0.001). CONCLUSIONS: Among STEMI patients undergoing primary PCI, elevated UA levels are an independent predictor of AKI.
BACKGROUND: Elevated serum uric acid (UA) levels are associated with adverse outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). However, the relation between UA and acute kidney injury (AKI) in this population is unclear. We evaluated the effect of elevated UA levels on the risk to develop AKI among consecutive STEMI patients treated with primary PCI. METHODS: We performed a retrospective analysis of 1,372 consecutive patients admitted with the diagnosis of STEMI between January 2008 and February 2015. Patients were stratified into quartiles according to UA levels as follows: quartile 1, <4.7 mg/dl; quartile 2, 4.8 to <5.6 mg/dl; quartile 3, 5.7 to <6.6 mg/dl, and quartile 4, >6.7 mg/dl. RESULTS: STEMI patients with elevated UA levels had a higher frequency of AKI (4 vs. 6% vs. 10 vs. 24%; p < 0.001). In a subgroup analysis of patients with reduced baseline estimated glomerular filtration rate (≤60 ml/min/1.73 m(2)), an elevated UA level was associated with a significant risk to develop AKI, with 46% of patients developing AKI in the highest UA quartile. In a multivariate logistic regression model, for every 1-mg/dl increase in the UA concentration, the adjusted risk for AKI increased by 46% (OR = 1.46, 95% CI 1.18-1.66; p < 0.001). CONCLUSIONS: Among STEMI patients undergoing primary PCI, elevated UA levels are an independent predictor of AKI.
Authors: Amit P Amin; John A Spertus; Kimberly J Reid; Xiao Lan; Donna M Buchanan; Carole Decker; Frederick A Masoudi Journal: Am Heart J Date: 2010-12 Impact factor: 4.749
Authors: A Ahsan Ejaz; Thomas M Beaver; Michiko Shimada; Puneet Sood; Vijaykumar Lingegowda; Jesse D Schold; Tad Kim; Richard J Johnson Journal: Am J Nephrol Date: 2009-09-11 Impact factor: 3.754
Authors: A Ahsan Ejaz; Wei Mu; Duk-Hee Kang; Carlos Roncal; Yuri Y Sautin; George Henderson; Isabelle Tabah-Fisch; Birgit Keller; Thomas M Beaver; Takahiko Nakagawa; Richard J Johnson Journal: Clin J Am Soc Nephrol Date: 2006-12-06 Impact factor: 8.237